Redhill Biopharma Ltd
RDHL
Company Profile
Business description
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
Contact
21 Ha’arba’a Street
Tel Aviv6473921
ISRT: +972 35413131
E: investors@redhillbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2024
Employees
53
Stocks News & Analysis
stocks
Are BHP shares attractive after results?
Solid start to the fiscal year from the ASX's largest miner.
stocks
Electric vehicle outlook hinges on more than just the US election
What to know about interest rates, electric vehicle tax credits, EV driving range, affordability, and more.
stocks
Taiwan Semiconductor earnings: Outstanding guidance fueled by AI conviction
Our view of TSMC shares after its impressive results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,551.20 | 72.90 | -0.85% |
| CAC 40 | 7,613.05 | 29.32 | 0.39% |
| DAX 40 | 19,657.37 | 73.98 | 0.38% |
| Dow JONES (US) | 43,275.91 | 36.86 | 0.09% |
| FTSE 100 | 8,358.25 | 26.88 | -0.32% |
| HKSE | 20,804.11 | 725.01 | 3.61% |
| NASDAQ | 18,489.55 | 115.94 | 0.63% |
| Nikkei 225 | 38,981.75 | 70.56 | 0.18% |
| NZX 50 Index | 12,823.89 | 55.35 | 0.43% |
| S&P 500 | 5,864.67 | 23.20 | 0.40% |
| S&P/ASX 200 | 8,283.20 | 72.70 | -0.87% |
| SSE Composite Index | 3,261.56 | 92.18 | 2.91% |